ArticleFrontiers in neurology2025
Clinical outcomes of endovascular treatment for acute basilar artery occlusion patients with extremely severe symptoms.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Beyond Time Is Brain: The Time, Tissue, and Systems Framework for Acute Stroke.Journal of central nervous system disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the effectiveness and safety of endovascular treatment (EVT) in acute basilar artery occlusion (ABAO) patients with extremely severe symptoms [National Institutes of Health Stroke Scale (NIHSS) score >25] in the real world. Methods: This study was a subgroup analysis of a prospective multicenter cohort study (EVT for Acute Basilar Artery Occlusion Study, BASILAR registry). Patients were categorized into EVT and standard medical treatment (SMT) groups. The primary effectiveness outcome was the distribution of modified Rankin Scale (mRS) scores at 90 days. Safety outcomes included 90-day mortality and symptomatic intracerebral hemorrhage (sICH) within 48 h. Results: Among 436 ABAO patients with extremely severe symptoms, 342 (78.4%) underwent EVT. Compared with SMT, EVT was significantly associated with greater odds of favorable shift in mRS distribution [adjusted OR (aOR) 3.98, 95% CI 2.02-7.84, Conclusions: In ABAO patients with extremely severe symptoms, EVT demonstrated superior functional outcomes and lower mortality. Minimizing onset to treatment time and puncture to reperfusion time is essential for optimizing clinical outcomes in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.